Health
Psychedelic drug discovery enabling discovery of new psychiatric drugs – Drug Target Review
Having resolved the structure of psychedelic drugs bound to the 5-HT2A serotonin receptor researchers are developing new therapeutic drugs.
Posted: 18 September 2020 | Hannah Balfour (Drug Target Review) | No comments yet
Having resolved the structure of psychedelic drugs bound to the 5-HT2A serotonin receptor researchers are now developing new therapeutic drugs.
Psychedelic drugs such as LSD, psilocybin, and mescaline cause severe and often long-lasting hallucinations, but also show great potential in treating serious psychiatric conditions, such as major depressive disorder. In order to understand their therapeutic effect, and p…
Continue Reading
